icone plus
Contact Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
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
U2nbyK2E0erz9gTG
Listen
